LEGALDIGMLEGALDIGM
    ← Code of Federal Regulations
    Beta
    21 CFR § 866.3336

    21 CFR § 866.3336 — § 866.3336 John Cunningham Virus serological reagents.

    Beta. Legal information, not legal advice. LEGALDIGM is not a law firm. Check the official source for the current text.

    Analyze this law with AI
    § 866.3336 John Cunningham Virus serological reagents. (a) Identification. John Cunningham Virus serological reagents are devices that consist of antigens and antisera used in serological assays to identify antibodies to John Cunningham Virus in serum and plasma. The identification aids in the risk stratification for the development of progressive multifocal leukoencephalopathy in multiple sclerosis and Crohn's disease patients undergoing natalizumab therapy. These devices are for adjunctive use, in the context of other clinical risk factors for the development of progressive multifocal leukoencephalopathy. (b) Classification. Class II (special controls). The special control for this device is the FDA guideline document entitled “Class II Special Controls Guideline: John Cunningham Virus Serological Reagents.” For availability of the guideline document, see § 866.1(e). [79 FR 3740, Jan. 23, 2014]

    Related guides, FAQ and contract templates